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Abstract Vitamin D is capturing the attention of healthy
and chronically ill populations for its potential skeletal and
nonskeletal benefits. New information suggesting a role in
immune modulation has led to a surge of interest among
rheumatologists. Although the epidemiologic data are
limited, it appears that many children with rheumatic
conditions are at risk of vitamin D deficiency. However,
understanding this phenomenon requires an appreciation for
how vitamin D status is assessed, and options for
supplementation. Although a “more-is-better” attitude is
tempting when considering the medicinal effects of a
nutritional supplement, we suggest a cautious approach
and suggest that further studies are needed to clarify the
potential benefits and risks among children with rheumatic
conditions.
Keywords Vitamin D . Child . Juvenile arthritis . Systemic
lupus erythematosus
Introduction
For many years, vitamin Dwas considered simply another fat-
soluble vitamin with important skeletal effects. However,
epidemiologic studies suggesting more widespread health
effects have led to a surge of interest in this vitamin. Examples
of newly identified health benefits include the prevention of
cancer, reduction of risk of myocardial ischemia, and
prevention and regulation of autoimmune disease. This has
led to a flood of studies examining the molecular interactions
of vitamin D and its role in disease, and clinical trials
examining the benefits of supplementation. Unfortunately,
despite these efforts, the suggested form of vitamin for
assessing nutritional status, the optimal level for health, and
the recommended dose for supplementation all remain
unclear. Among pediatricians, the perceived potential benefit
of vitamin D for maximizing peak bone mass and preventing
osteoporosis combined with a strong interest among pro-
viders, patients, and parents to use “safe” medications has led
to an eagerness to supplement children with rheumatic
conditions with vitamin D. In this report, we describe the
current understanding of the biologic mechanisms of vitamin
D with a focus on their relevance to children with rheumatic
diseases. Additionally, we provide a summary of the clinical
trial experience to date for vitamin D supplementation. The
emerging story will demonstrate the importance of this
nutrient and the need for future studies. Unfortunately, due
to limited data available at this time, particularly in children
with chronic illnesses, no consensus exists about how best to
approach this important phenomenon in the pediatric rheu-
matology clinic.
Biologic Effects of Vitamin D
Vitamin D3 may be ingested from dietary sources such as
fortified milk or oily fish, or derived from the conversion of
7-dehydrocholesterol to previtamin-D3 by solar UVB
radiation. Vitamin D3 is transported to the liver, where it
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is converted to 25-hydroxyvitamin D (25[OH]D), the best
single determinant of vitamin D status [1, 2]. Production of
the active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25[OH]2D) via the 25(OH)D-1α-hydroxylase
(CYP27B1) enzyme in the proximal tubular epithelial cells
of the kidney is tightly regulated by serum parathyroid
hormone (PTH), calcium, and phosphorous concentrations
[1].
1,25(OH)2D impacts gene transcription by binding to the
vitamin D receptor (VDR). The VDR forms a heterodimer
with the retinoid X receptor in the cytoplasm, which
translocates into the nucleus and binds to vitamin D
response elements in vitamin D-responsive genes. The
classic endocrine actions of 1,25(OH)2D are to increase
intestinal calcium and phosphate absorption and to induce
expression of receptor activator of nuclear factor-κB ligand
in osteoblasts. The latter function results in the maturation
of osteoclasts and increased bone resorption, which allows
for release of calcium into the bloodstream [3]. Recent
attention has focused on local intracrine or paracrine effects
of vitamin D whereby 25(OH)D is converted locally into
1,25(OH)2D in immune cells, pancreatic β cells, and
vascular smooth muscle cells, for example. Local produc-
tion of 1,25(OH)2D may be adversely impacted by 25(OH)
D deficiency [4].
Effects of Vitamin D on Bone and Muscle
Extreme 25(OH)D deficiency causes rickets in growing
children and osteomalacia after skeletal maturation [5].
Rickets causes pain, bowing and splaying of long bones,
and infections [5]. Vitamin D supplementation in adults
results in a lowering of fracture risk, likely via suppression
of PTH-induced excess bone remodeling, improvements in
bone mass, and prevention of falls [6].
Some supplementation studies in girls suggest a role for
vitamin D to maximize bone mass, muscle mass, and
muscle function. In one study of 179 Lebanese girls 10 to
17 years of age, vitamin D3 supplementation was provided
for a period of 1 year [7]. Compared with placebo, low-
dose (1,400-IU/wk) supplementation improved lumbar
spine bone density. Low- and high-dose (14,000-IU/wk)
regimens improved lean mass and bone mineral content in
the trochanteric region of the hip. These improvements
were limited to girls prior to menarche. In a randomized
clinical trial in Finland, 228 girls were randomly assigned
to placebo, 200 IU/d, or vitamin D3, 400 IU/d, for 1 year
[8]. Positive effects of supplementation on bone mineral
content were noted in the femur (low- and higher-dose
groups) and the spine (higher-dose group), in which the
effects were more pronounced in mid-pubertal girls. Urine
deoxypyridinoline, a bone resorption marker, was reduced
significantly. Limitations of this study included restriction
of the analysis to those who were adherent to the
supplementation regimen, and given the low doses of
vitamin tested, the effects on serum 25(OH)D concentra-
tions were modest. A recent study of 73 postmenarchal girls
12 to 14 years of age assessed bone mass and musculo-
skeletal function [9]. Participants had 25(OH)D concen-
trations less than 15 ng/mL and were randomly assigned to
placebo or four doses of vitamin D2, 150,000 IU every
3 months. No change was observed in bone mass, but
muscle function improved significantly, particularly among
those with the lowest baseline 25(OH)D concentrations.
Together, these studies suggest a potential benefit on
musculoskeletal outcomes, particularly in girls prior to
menarche.
Effects of Vitamin D on Glucose Homeostasis
Vitamin D impacts insulin secretion and insulin sensitivity.
Deficiency in rats caused lower insulin secretion by
pancreatic islet cells [10]. 1,25(OH)2D may increase insulin
production by modulating β-cell growth and increasing
cytosolic calcium concentrations in β cells, which may
increase exocytosis of insulin, glycogenolysis, and the
conversion of proinsulin to insulin [11]. The mechanism
by which vitamin D deficiency impacts insulin resistance is
not fully understood but may be mediated indirectly by
vitamin D effects on inflammation or secondary hyperpara-
thyroidism [11]. In nondiabetic adults, lower 25(OH)D
levels were predictive of lower insulin sensitivity after
adjustment for sex, age, race, blood pressure, and body
mass index [12]. These data likely translate to the pediatric
population. In 3577 nondiabetic American adolescents
enrolled in the National Health and Nutrition Examination
Survey (2001–2004), those with the lowest 25(OH)D
concentrations had a significantly greater risk of fasting
hyperglycemia and the metabolic syndrome [13]. In African
American adolescent females, a 25(OH)D concentration of
less than 15 ng/mL was associated with significantly
greater insulin resistance after an oral glucose challenge
[14]. To date, however, clinical trials of vitamin D
supplementation in adults with normal glucose tolerance
have not consistently shown benefits on fasting glucose or
diabetes risk [15]. However, one study showed a lower
increase in fasting glucose concentrations in adults with
impaired glucose tolerance prescribed vitamin D3 (700 IU/
day) and calcium for 3 years. To date, the role of vitamin D
supplementation in glucose homeostasis in children has not
been systematically evaluated.
Cardiovascular Effects of Vitamin D
Vitamin D may exert protective cardiovascular effects via
pleiotropic actions, including—but not limited to—regulation
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of the renin-angiotensin system, inhibition of vascular smooth
muscle proliferation and function, reduction of inflammation
and insulin resistance, and promotion of anticoagulant
properties of monocytes [15]. In adolescents, a 25(OH)D
concentration of less than 15 ng/mL was associated with a
greater than twofold risk of hypertension [13]. This effect
was independent of age, sex, race, physical activity, and
body mass index. In some observational studies, vitamin D
deficiency has been associated with incident cardiovascular
disease [16, 17] and death from cardiovascular events such
as myocardial infarction and stroke [18, 19]. Vitamin D
supplementation trials in adults suggest a potential benefit,
particularly systolic blood pressure, but have not yet
demonstrated a significant benefit with regard to cardiovas-
cular events [15].
Immunologic Effects of Vitamin D
Vitamin D is a recognized regulator of immune function
(Table 1). By enhancing macrophage production of antimi-
crobial peptides, vitamin D may play a critical role in the
clearance of mycobacterial infections [20]. Conversely,
vitamin D suppresses proinflammatory properties of dendritic
cells (DCs) [21], antigen-presenting cells that stimulate
immune responses, prevent autoimmunity, and link the innate
and adaptive immune response. These immunomodulating
effects have potential implications for a variety of autoim-
mune conditions, including—but not limited to—systemic
lupus erythematosus (SLE), juvenile dermatomyositis, juve-
nile idiopathic arthritis, and multiple sclerosis [22].
Although there are specific effects of vitamin D on T cells,
vitamin D effects on myeloid DCs likely drive changes in T-
cell activity [23••]. VDR agonists decrease DC expression of
CD40, CD80, CD86, and interleukin (IL)-12 and increase
IL-10 expression, indicating that the main effects of vitamin
D are to decrease T-cell stimulation and increase immune
tolerance. 1,25(OH)D significantly decreased interferon-α
and granulocyte-macrophage colony-stimulating factor-
induced expression of DC maturation and activation
markers. Reduced expression of IL-12 by DCs with VDR
agonists suppresses T-helper type 1 (Th1) development [24],
while greater IL-10 expression promotes regulatory T-cell
(Treg) development [25]. In an experimental colitis model,
amelioration of disease by vitamin D was thought to be due
to induction of Tregs and reductions in IL-12, IL-23, and IL-
6 [26]. IL-12 inhibition reduces Th1 development, while IL-
6 and IL-23 inhibition reduce Th17 development. VDR
agonists can modulate T-cell function by altering DC
chemokine expression. One VDR agonist, BXL-219,
inhibited effector T-cell recruitment in a type 1 diabetes
model by inhibiting proinflammatory chemokine production
[27]. Immature myeloid DCs produce CCL17 and CCL22,
chemokines that attract cells expressing CCR4, a receptor
that is present on Tregs. Myeloid DC production of CCL22
is augmented by VDR agonists [24]. In the epidermis, active
vitamin D produced by DCs in response to sunlight
upregulates T-cell expression of CCR10. This chemokine
receptor binds CCL27, which directs epidermal migration. It
is hypothesized that Tregs migrate to the epidermis to
counteract inflammation associated with sun exposure.
Vitamin D has been found to regulate B-cell development,
survival, and function. An effect of vitamin D is supported by
the upregulation of the VDR with B-cell stimulation or
addition of 1,25(OH)2D, and the ability of B cells to
metabolize 25(OH)D into 1,25(OH)2D [28]. 1,25(OH)2D
significantly inhibited B-cell proliferation when stimulated
with anti-IgM, anti-CD40, and IL-21 and enhanced their
apoptosis. Plasma cell differentiation, post-switch memory
B-cell differentiation, and immunoglobulin secretion were
inhibited by 1,25(OH)2D. Together, these data suggest that
1,25(OH)2D reduces B-cell hyperactivation.
Interrelationship of Vitamin D and Cancer
An inverse relationship between sun exposure and mortality
among patients with colon and prostate cancer first
suggested the potential beneficial effect of vitamin D in
cancer [29]. Many genes that influence proliferation,
invasiveness, angiogenesis, metastatic potential, differenti-
ation, and apoptosis have been demonstrated to be under
the influence of vitamin D [30] However, evidence also
supports a potential negative effect of vitamin D on cancer,
demonstrating the need for further studies in this area.
Potential Importance of Vitamin D in Pediatric
Autoimmune Diseases
Vitamin D represents an appealing therapy in pediatric
rheumatic diseases. Its myriad effects may both minimize
Table 1 Immunologic effects of vitamin D that may influence
autoimmune diseases
Cell type Vitamin D effect
Dendritic cells ↓CD40, CD80, CD86, IL-12 expression
↑IL-10 expression
↑Chemokines that attract Tregs
T cells ↓Th1 and Th17 action (possible)
↑Tregs
B cells ↓Proliferation and differentiation
↑Apoptosis
IL—interleukin; Th1—T-helper type 1; Th17—T-helper type 17; Treg—
regulatory T cell
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disease-related comorbidities such as bone fragility [31],
accelerated cardiovascular disease, and infections and
attenuate the immune hyperactivation that is characteristic
of conditions such as pediatric SLE [32•] and multiple
sclerosis. In pediatric SLE patients with 25(OH)D less than
20 ng/mL, the SLE Disease Activity Index scores were
significantly higher. This finding in children was replicated
in a more recent study conducted in a larger, multicenter
cohort of 198 adults with SLE [33]. Additionally, lower 25
(OH)D concentrations were associated with a greater
relapse rate in pediatric multiple sclerosis [34]. Randomized
clinical trials in pediatric rheumatic diseases will be
required to determine whether vitamin D supplementation
diminishes disease activity and damage.
Defining Optimal Vitamin D Status
Although 1,25(OH)2D is the active form of vitamin D, it
has a very short half-life, and in the early stages of vitamin
D deficiency, while 25(OH)D falls, 1,25(OH)2D can remain
normal or even rise. Thus, 25(OH)D is the usual recom-
mended vitamin D metabolite for assessing total stores
[35••]. However, interpretation of the vitamin D level and
defining adequacy remain controversial. For many years, a
“normal” vitamin D level was defined as that level
necessary to maintain a normal PTH. However, emerging
data suggesting more pleiotropic effects of vitamin D and a
focus on maintaining bone health have led to the suggestion
that ideal vitamin D levels may be higher than originally
suggested. Today, most reference laboratories still provide a
wide range for “normal,” reflecting the now-recognized
hypovitaminosis D commonly seen in otherwise-well
individuals and the fact that the definition of “sufficiency”
remains controversial. However, most experts today define
vitamin D deficiency as a 25(OH)D level less than 20 ng/
mL (50 nmol/L), insufficiency as a level between 21 and
29 ng/mL (52–72 nmol/L), and optimal levels greater than
30 ng/mL (70 nmol/L) [36–38]. Whether these recommen-
dations apply to children and adolescents remains unclear.
Furthermore, it is not yet clear whether the same definition
of vitamin D sufficiency applies to children with rheumatic
disease as to those who are otherwise healthy.
Vitamin D Deficiency: Identifying At-Risk Populations
Several features are now well-recognized from epidemio-
logic studies as important risk factors for vitamin D
deficiency in children. Due to the relatively low concen-
trations of vitamin D in most foods, sun exposure
historically has been the greatest source of vitamin D for
humans. Thus, anything that reduces exposure to UVB
radiation may contribute to low vitamin D production. This
includes living at higher latitudes, increased time spent
indoors, use of sunscreen, and darker skin pigmentation [1,
2, 39]. A study of obese adolescents demonstrated a
significant correlation between reduced 25(OH)D levels
and obesity as assessed by abdominal CT measurements of
visceral fat [40]. Given the rise in obesity, this association
suggests an important risk factor for vitamin D status and
possible pathways for the action of vitamin D on health.
Although vitamin D insufficiency has been demonstrated
in several adult studies of rheumatic disease patients,
studies in children are limited. Observed reductions in
vitamin D levels in these patients may result from the same
risk factors observed in otherwise-healthy individuals, or
from direct effects of the disease and its associated
treatment. In a study of children with diverse rheumatic
diseases, low vitamin D levels were observed in juvenile
idiopathic arthritis, SLE, and juvenile dermatomyositis
[41]. However, in a study focused on children with juvenile
rheumatoid arthritis, 25(OH)D levels were actually higher
in the children with the oligoarticular subtype of juvenile
idiopathic arthritis [42]. One challenge in interpreting the
results of these studies is the background prevalence of
vitamin D deficiency among healthy individuals, as the
mean 25(OH)D level in these healthy children was also low
(22.0±8.5 ng/mL). Very few studies of vitamin D status
have been conducted in childhood SLE, but the co-author
of this article (Dr. Burnham) reported in a cohort of 38
children with SLE that severe vitamin D deficiency (25
[OH]D<10 ng/mL) was more frequently seen in those with
SLE than in healthy controls (36.8% vs 9.2%), and there
was a strong association with obesity [32•]. This is similar
to that reported in adult SLE cohorts [43••]. Furthermore,
reduced vitamin D levels appear to be a very common
problem in SLE, with a large Canadian study of women
with SLE demonstrating suboptimal levels of 25(OH)D in
66% and deficiency in 17.9% of women [44].
Although more epidemiologic studies are needed to help
us better understand which children with rheumatic diseases
are at greatest risk of developing vitamin D deficiency, the
compelling data pointing to a role for vitamin D in immune
regulation suggest that special attention should be paid to
these at-risk populations.
Approach to Vitamin D Supplementation in Children
with Rheumatic Conditions
The goal of vitamin D supplementation is to reverse 25
(OH)D deficiency or to maintain optimal 25(OH)D con-
centrations. In 2008, the American Academy of Pediatrics
increased the recommended minimum daily intake of
vitamin D from 200 to 400 IU for infants, children, and
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adolescents and stated that serum 25(OH)D levels should
be maintained at greater than 20 ng/mL [35••]. However,
observational data examining skeletal and nonskeletal
outcomes suggest that a 25(OH)D level of 30 ng/mL
should be the minimum cut point for vitamin D sufficiency
[45]. Recently released Institute of Medicine guidelines
focused on the recommended intake to ensure adequate
bone health in otherwise-healthy individuals and suggested
600 IU/d for healthy children [46••]. This study also
highlighted the concern that excessive intake of vitamin D
may be harmful and that further studies are needed to help
us better understand the tolerable upper limit of intake to
prevent toxicity. All supplementation strategies should be
designed to achieve a target 25(OH)D concentration.
Vitamin D may be supplemented in active or inactive
forms. Supplementation with active vitamin D (1,25[OH]2D)
carries a risk of hypercalcemia [47] and is generally reserved
for individuals with chronic kidney disease because the
kidney is a main site at which 25(OH)D is converted to 1,25
(OH)2D. Among those individuals able to convert 25(OH)D
to 1,25(OH)2D, supplementation with vitamin D2 (ergocal-
ciferol) or D3 (cholecalciferol) is preferred, as the 25(OH)D
is the required substrate for conversion to 1,25(OH)2D at the
cellular level. Vitamin D2 does not have the long-term
potency of D3. When adults were supplemented with a
single 50,000-IU dose of vitamin D2 or D3, 25(OH)D levels
increased equivalent amounts in the first 3 days after
supplementation. However, by 2 weeks, D2 levels were not
greater than presupplementation levels. In contrast, D3 levels
were still greater than baseline at 28 days after supplemen-
tation [48]. Similarly, supplementation with 4,000 IU of D3
for 14 days yielded significantly greater increases in 25(OH)
D than those supplemented with an equivalent dose of D2
[49]. In adults, each 1,000 IU of vitamin D3 per day
increased 25(OH)D levels by 7 to 10 ng/mL [50].
Recent studies demonstrated the safety and efficacy of
vitamin D3 supplementation in pediatric populations.
Children with neuromuscular disorders received vitamin
D3, 1,000 IU/d for 5 d/wk, or no supplementation for
10 weeks [51]. 25(OH)D levels increased by about 5 ng/mL
in the supplementation group and decreased by 2 ng/mL in
the untreated group. Weekly supplementation of 14,000 IU
of vitamin D3 for 8 weeks in vitamin D-replete Lebanese
adolescents resulted in a significant increase in 25(OH)D
concentrations compared with placebo. None of the
participants developed vitamin D toxicity, defined as
elevations of serum calcium and 25(OH)D in the same
individual. In a 1-year study of Lebanese children and
adolescents 10 to 17 years of age, participants received
vitamin D3 at 0, 1,400, or 14,000 IU/wk [7]. The mean
baseline 25(OH)D was 14 ng/mL. After supplementation,
25(OH)D levels in the three groups were 16, 17, and 38 ng/
mL in girls and 17, 20, and 35 ng/mL in boys, respectively.
No hypercalcemia was observed in those receiving vitamin
D3. Three individuals in the high-dose group experienced
serum 25(OH)D levels up to 195 ng/mL, but concomitant
hypercalcemia was not observed. None of the participants
in the latter two studies developed vitamin D toxicity,
defined as elevations of serum calcium and 25(OH)D in the
same individual. Thus, vitamin D supplementation of up to
2,000 IU/d appears to be safe and well-tolerated in daily or
weekly dosing regimens.
Looking to the Future
Current interest in the pleiotropic effects of vitamin D
and the potentially important therapeutic benefits for
health is anticipated to spawn continued studies in this
area. The challenges to date in demonstrating efficacy of
nutritional supplements using traditional clinical trial
designs are a legitimate concern that must be addressed
to clarify the best approach to vitamin D supplementa-
tion. Further research is needed to elucidate the optimal
level for health across the age spectrum, to develop safe
and effective supplementation strategies, and to deter-
mine the highest safe level for vitamin D. Through
future studies, new roles for vitamin D in health and
disease are likely to emerge, resulting in additional
indications for monitoring and supplementation.
Conclusions
Current evidence suggests that many children and adoles-
cents are affected by vitamin D deficiency, and those with
rheumatic diseases are at particular risk of the negative
consequences of suboptimal vitamin D stores. In addition to
the skeletal concerns for patients with rheumatic conditions,
maintaining optimal vitamin D stores may actually serve an
important role for controlling the underlying immune
hyperactivation. Thus, it is recommended that these patients
be screened and counseled on the importance of ensuring
adequate intake. In the absence of specific guidelines for
children with rheumatic conditions, the American Academy
of Pediatrics guidelines provide useful minimum dosing
regimens for children. However, it is important to recognize
that further studies are needed to determine if the beneficial
effects in at-risk populations are comparable with those in
healthy populations.
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